An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Jun 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Gynaecological cancer; Head and neck cancer; Prostate cancer; Solid tumours
Focus Pharmacodynamics; Therapeutic Use
Acronyms AMADEUS

11 Jul 2023 Status changed from active, no longer recruiting to completed.
28 Oct 2022 Status changed from recruiting to active, no longer recruiting.
07 Jun 2022 Planned primary completion date changed from 1 May 2022 to 1 Dec 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com